<DOC>
	<DOCNO>NCT02666131</DOCNO>
	<brief_summary>The purpose study determine whether Granexin gel safe effective treatment diabetic foot ulcer .</brief_summary>
	<brief_title>A Study Granexin Gel Treat Diabetic Foot Ulcer</brief_title>
	<detailed_description>DFU patient undergo one week screen period change ulcer size le 30 % eligible randomization provide criterion meet . Participants enrol study receive treatment base randomization 1 2 treatment arm 12 week . The participant additional 12 week follow-up period beyond treatment period assess durability wound closure .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>1 . Age 18 year old 2 . Established diagnosis diabetes mellitus ( type I II ) 3 . Glycosylated hemoglobin ( HbA1c ) value &lt; 10.0 % screen visit 4 . Diagnosis neuropathic foot ulcer 10g monofilament test , tune fork ( 128 Hz ) , cotton wisp , quantitative sensory test 5 . Designated foot ulcer meet follow criterion screen baseline visit : . Present least 4 week ; b. Fullthickness cutaneous ulcer ankle surface ; c. University Texas grade A1 ; d. Diameter ( debridement ) 1 40.0 cm2 ; e. Viable , granulate wound ( investigator discretion ) 6 . Ankle brachial index 0.7 1.3 screen baseline visit 7 . Signed informed consent 8 . Female patient childbearing potential must negative pregnancy test screening must agree use hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence throughout 2 week last administration study drug 1 . Change ( decrease increase ) size designate target ulcer ≥ 30 % 7day screening period 2 . Can tolerate offload method comply studydefined standardofcare treatment 3 . Has ulcer meet follow criterion : . Shows sign severe clinical infection , define pu ooze ulcer site ; b . Requires operative debridement ; c. Is positive βhemolytic streptococci upon culture ; d. Has &gt; 50 % slough , significant necrotic tissue , bone , tendon , capsule exposure ; e. Is highly exude ( i.e. , require daily change dress ) 4 . Requires total contact cast 5 . Ankle brachial pressure index &lt; 0.7 &gt; 1.3 ankle systolic pressure &lt; 70 mmHg 6 . Has local systemic infection local erythema ≥ 0.5 cm 7 . Has 1 follow ( 1 3 test require ) : . On Doppler waveform analysis dorsalis pedis posterior tibial artery , monophasic biphasic flow ( loss reverse flow ) either artery either foot ; b. Toe : brachial index &lt; 0.75 &gt; 1.3 c. Transcutaneous oxygen pressure &lt; 40 mmHg 8 . Presence active systemic local cancer tumor kind ( exception : nonmelanoma skin cancer allowable investigator discretion ) 9 . Congestive heart failure ( New York Heart Association class IIIV ) coronary heart disease ST segment elevation myocardial infarction coronary artery bypass graft percutaneous transluminal coronary angioplasty within last 6 month 10 . Active osteomyelitis foot target ulcer detect xray , CT scan , MRI 11 . Active connective tissue disease 12 . Acute Charcot 's neuroarthropathy determine clinical and/or radiographic examination 13 . Active treatment systemic corticosteroid 14 . Previous current radiation therapy distal low extremity likelihood receive therapy study participation 15 . Pregnant nursing 16 . Uncontrolled anemia ( hemoglobin &lt; 10 g/dL female &lt; 12 g/dL male ) 17 . Estimated glomerular filtration rate &lt; 25 mL/min 18 . Poor nutritional status , define albumin &lt; 25 g/L ( &lt; 2,500 mg/dl ) 19 . Significant peripheral edema per investigator 's discretion 20 . Known inability unavailability complete require study visit study participation 21 . A psychiatric condition ( e.g. , suicidal ideation ) chronic alcohol drug abuse problem , determine patient 's medical history , , opinion investigator , may pose threat patient compliance 22 . Use plateletderived growth factor within 28 day screen 23 . Use investigational drug therapy within 28 day screen 24 . Has factor may , opinion investigator , compromise participation and/or followup study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>diabetic foot ulcer</keyword>
	<keyword>diabetic complication</keyword>
	<keyword>diabetes</keyword>
	<keyword>wound healing</keyword>
	<keyword>Granexin gel</keyword>
	<keyword>FirstString Research</keyword>
</DOC>